Edgewood Oncology Unveils Compelling Preclinical Data Supporting BTX-A51 in Liposarcoma at AACR Annual Meeting 2025 Edgewood Oncology, a clinical-stage biotechnology company dedicated to advancing targeted cancer therapies, today announced new preclinical efficacy data for BTX-A51 in liposarcoma (LPS). The data,…
Mythic Therapeutics Presents Promising Preclinical Data Demonstrating Broad Antitumor Efficacy of MYTX-011 at the 2025 AACR Annual Meeting Mythic Therapeutics, a clinical-stage biotechnology company pioneering the next generation of antibody-drug conjugates (ADCs), today unveiled compelling preclinical data supporting the broad…
Devonian Health Group Inc. Announces Reinstatement of Trading on TSX Venture Exchange Following Resolution of Cease Trade Order Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a late-stage botanical pharmaceutical corporation, today announced a significant corporate…
Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented new clinical data on its lead drug candidate, neratinib (NERLYNX®),…
Agenus Presents Promising BOT/BAL Neoadjuvant Pan-Cancer Data from NEOASIS Study at AACR Annual Meeting Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing therapies designed to activate the body’s immune system to fight cancer, announced the presentation of…
LEAP Consulting Group Accelerates Clinical Lab Digital Transformation with Appointment of Dr. Heather E. Williams as Practice Principal, Life Sciences LEAP Consulting Group, a boutique digital consultancy recognized for its domain expertise in the clinical diagnostics space, has announced a…
Fellow Health to Present Groundbreaking Research on Prostate Cancer Biomarkers and Mail-In PVSA Testing at AUA 2025 Fellow Health, a pioneering healthcare company dedicated to advancing male reproductive health through innovative, patient-centered diagnostics, today announced that it will present four…
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development, Signaling Strategic Growth in Clinical Pipeline Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company advancing novel treatments for serious central nervous system (CNS) and immunologic…
Medifast Reports First Quarter 2025 Financial Results, Focuses on Revitalizing Growth and Enhancing Wellness Offerings Medifast, a leading health and wellness company known for its clinically supported and coach-guided lifestyle solution, OPTAVIA®, has announced its financial results for the first…
Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power of artificial intelligence (AI) to revolutionize in vivo gene delivery,…
Obsidian Therapeutics to Present Groundbreaking Preclinical Data on cytoDRiVE® Platform at the 2025 ASGCT Annual Meeting Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to cell and gene therapy through synthetic biology, has announced the acceptance of a…
Sangamo Therapeutics to Highlight Neurology Pipeline Innovations with Nine Presentations at 28th ASGCT Annual Meeting Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company focused on developing transformative therapies for serious neurological conditions, announced that nine of its scientific abstracts…